Clinical Observation Of "Bushen Huoxue" Prescr Iption In Treating Patients With Chronic Kidney Disease(CKD3-5) Stage

Objective:To observe the safety as well as the clinical efficiency of "Bushen Huoxue"prescription in treating patients with chronic kidney disease(CKD).Methods:(1)A total of 60 cases will randomly taked into groups in chronic kidney disease in patients with stage 3-5 "kidney and blood stasis" diagnostic criteria,in/out/off and termination criteria,using the random number table method,divided into observation group and controlled group,30 cases in each group.(2)Two groups are in western medicine symptomatic treatment,the observation group was given "Bushen HuoxueFa" method of treatment,daily 1 agent,2 times in the morning and evening,taken 30 minutes after the meal;The control to the proprietary Chinese medicine uric poisonous clear grain,1 bag each time,qid.(3)In the two groups were recorded before and after therapy in patients with hemoglobin,renal function(including blood urea nitrogen,serum creatinine,uric acid)and glomerular filtration rate,clinical symptoms integral,calculate the total treatment in both groups,statistical analysis method of "BushenHuoxueFa,treating CKD3-5 to assess the efficacy and safety of patients.Results:All the patients completed the course of 2 months of treatment.Before the treatment,the patient's hemoglobin,renal function(including blood urea nitrogen,serum creatinine,uric acid)and glomerular filtration rate,clinical symptoms integral statistical analysis,there were no significant differences.After treatment,patients with hemoglobin,urea nitrogen,Chinese medicine symptom integral aspect in the two groups were improved,and the observation group is better than the controlled group.Patients' GFR,serum creatinine,as well as uric acid in blood are decreased in the two groups after treatment.The observation group difference was statistically significant,the controlled group not significant.Conclusion:"BuShenHuoXueFa" method for the treatment of chronic kidney disease stage 3-5 patients is superior to uric poisonous clear grain group.It has no obvious adverse reactions,worthy of more large sample of clinical research,for the future in clinic to provide sufficient evidence of evidence-based medicine.